ERMA — Enorama Pharma AB Income Statement
0.000.00%
Last trade - 00:00- SEK172.00m
- SEK169.92m
- SEK15.77m
Annual income statement for Enorama Pharma AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | Interim Report | ARS | ARS | ARS |
| Standards: | SAS | — | SAS | SAS | SAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 2.15 | 11 | 6.85 | 1.36 | 15.8 |
| Cost of Revenue | |||||
| Gross Profit | 2.76 | 3.9 | -0.616 | -3.9 | 3.7 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 25.2 | 38 | 48.3 | 43.5 | 63.3 |
| Operating Profit | -23 | -26.9 | -41.5 | -42.1 | -47.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -23.5 | -27.7 | -42 | -44.6 | -43.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -23.5 | -27.7 | -42 | -44.6 | -43.8 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -23.5 | -27.7 | -42 | -44.6 | -43.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -23.5 | -27.7 | -42 | -44.6 | -43.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.41 | -3.62 | -4.34 | -1.41 | -0.547 |
| Dividends per Share |